LLY Oct 2024 600.000 call
| Previous Close | 190.58 |
| Open | 190.58 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 600.00 |
| Expire Date | 2024-10-18 |
| Day's Range | 190.58 - 190.58 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 23 |
ZacksZacks Investment Ideas feature highlights: Eaton, Eli Lilly and Arista Networks
Eaton, Eli Lilly and Arista Networks have been highlighted in this Investment Ideas article.
- Reuters
UPDATE 2-India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says
Cipla is open to partnering with U.S. drugmaker Eli Lilly to market its blockbuster obesity treatment drugs in India, the company's CEO said on Friday. Global demand has outpaced supply for Lilly's Mounjaro and Zepbound as well as Danish rival Novo Nordisk's Wegovy and Ozempic. Sensing the market opportunity, Indian drugmakers, including Cipla, are working to develop their copycat versions of the weight-loss drugs to aggressively grab a larger share in the market in the world's most populous country.
Zacks3 Stocks to Buy Following Guidance Upgrades
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture. And that's precisely what these three companies have recently announced.
